IN8bio to Present at Sidoti Small-Cap Virtual Conference

IN8bio’s CEO will present its γδ T cell platform and pipeline to investors at the Sidoti Small-Cap Virtual Conference via live webcast.

Rhea-AI Summary

IN8bio (INAB) will present at the Sidoti Small-Cap Virtual Conference on Thursday, September 24, 2026, at 1:00 p.m. ET.

Chief Executive Officer and Co-Founder William Ho will deliver a company presentation and hold one-on-one investor meetings during the September 23–24, 2026 event. The presentation will cover IN8bio’s differentiated γδ T cell platform, its pipeline, lead T cell engager program INB-619, and clinical-stage oncology programs. A live webcast and subsequent replay will be accessible via the Investors section of IN8bio’s website, with registration hosted on the Sidoti Zoom webinar platform.

Key Figures

Presentation date: September 24, 2026

Presentation date

September 24, 2026

Sidoti Small-Cap Virtual Conference

Key Terms

γδ t cell therapies, t cell engagers

2 terms

γδ t cell therapies medical

"developing innovative gamma-delta (γδ) T cell therapies"

A class of cell therapies that use or modify a rare subset of immune cells called gamma-delta (γδ) T cells to recognize and kill diseased cells, most often cancer. These therapies may expand, engineer, or transplant γδ T cells to exploit their innate-like ability to detect stressed or abnormal cells without the strict tissue-matching required by conventional T cells. Investors care because γδ approaches represent a distinct, potentially scalable segment of the immunotherapy market with different manufacturing, regulatory, and commercial implications than other cell treatments.

t cell engagers medical

"and T cell engagers for cancer and autoimmune diseases"

T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026.

Mr. Ho will participate in one-on-one meetings with investors throughout the conference and deliver a company presentation on Thursday, September 24. The presentation will provide an overview of IN8bio’s differentiated γδ T cell platform and pipeline, including its lead T cell engager program, INB-619, and clinical-stage programs in oncology.

Sidoti Small-Cap Virtual Conference
Date: Thursday, September 24, 2026
Time: 1:00 p.m. ET
Presenter: William Ho, Chief Executive Officer and Co-Founder
Webcast: https://sidoti.zoom.us/webinar/register/WN_bRXGkMX_Tqy0GgJJ6QJ4qg

A live webcast of the presentation will be available through the Investors section of IN8bio’s website. A replay will be available following the event.

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Investors and Corporate Contact:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors access IN8bio’s presentation at the Sidoti Small-Cap Virtual Conference?

A live webcast of William Ho’s presentation will be available through the Investors section of IN8bio’s website, with registration handled via a Sidoti Zoom webinar link. A replay will also be available on the company’s site following the event.